Tom Morris

BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARS

Manfred P. Wirth, William A. See, David G. McLeod et al. · The Journal of Urology · 2004 · 209 citations

Medicine, Oncology, Pharmacotherapy +13

Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

Laurence Collette, Tomasz Burzykowski, Kevin J. Carroll et al. · Journal of Clinical Oncology · 2005 · 110 citations

Medicine, Biostatistics, Oncology +17

BICALUTAMIDE (150 MG) VERSUS PLACEBO AS IMMEDIATE THERAPY ALONE OR AS ADJUVANT TO THERAPY WITH CURATIVE INTENT FOR EARLY NONMETASTATIC PROSTATE CANCER: 5.3-YEAR MEDIAN FOLLOWUP FROM THE SCANDINAVIAN PROSTATE CANCER GROUP STUDY NUMBER 6

Peter Iversen, Jan‐Erik Johansson, Pär Lodding et al. · The Journal of Urology · 2004 · 99 citations

Medicine, Oncology, Pharmacotherapy +14

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia

Christopher Tyrrell, H. Payne, Teuvo L.J. Tammela et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 99 citations

Medicine, Oncology, Radiation Oncology +8

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

Peter Iversen, Manfred P. Wirth, William A. See et al. · Urology · 2004 · 18 citations

Medicine, Oncology, Urology +14